Aboite Counseling

Home » Archives » September 2014 » Zyprexa, Cymbalta Fuel Growth for Lilly

[Previous entry: "Autism and Vaccines: Pediatricians Speak Out"] [Next entry: "Mental Health: Fourth Most Expensive Condition to Treat"]

09/14/2014: "Zyprexa, Cymbalta Fuel Growth for Lilly"

January 29, 2008

Filed under: Depression, Disorders, Healthcare, Indiana, Local (Central IN) News, Marion county, Pharmacology, psychiatrist, psychiatry, Rx Meds, Rx Meds: Cymbalta, Rx Meds: Zyprexia kurtglmft @ 11:22 am
Tags: Cymbalta, Eli Lilly, Indiana, Lilly, sales growth, Sidney Taurel, Zyprexa

From the Indianapolis Star:

Driven by solid sales of its antidepressant Cymbalta, Indianapolis drugmaker Eli Lilly and Co. today said fourth-quarter profits grew to $854.4 million and 78 cents per share, beating many analysts' estimates.

Earnings jumped six-fold from the same period in 2006, when Lilly recorded income of $132.3 million and 12 cents per share as it took a big charge to settle claims with patients who said they were harmed by Lilly's Zyprexa schizophrenia drug.

But showing how little harmed it was by that publicity, Lilly said Zyprexa sales were again No. 1 in its sales lineup, accounting for $1.27 billion. Cymbalta was next up with $628.3 million. Overall, its sales increased 16 percent to $5.19 billion.

"Lilly completed a very successful year by continuing to deliver strong financial results to our shareholders in the fourth quarter," said CEO and chairman Sidney Taurel. "Our additional investment in sales and marketing helped fuel accelerated double-digit sales growth."

New Comment
smile shocked sad
big grin razz *wink wink* hey baby
angry, grr blush confused
cool crazy cry
sleepy hehe LOL
plain jane rolls eyes satisfied
  Save Info?

Helping Individuals and Families... Get a clearer Picture!!!

Aboite Counseling and Therapy Group * 7311-B West Jefferson Blvd. * Fort Wayne * Indiana * 46804 * (260) 432-2311